Source: Annual Congress 2003 - Management of asthma in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. M. Rodriguez, S. Sondhi (Tres Cantos, Spain; London, United Kingdom). Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain. Eur Respir J 2003; 22: Suppl. 45, 2255

Member's Comments

No comment yet.

Related content which might interest you: Economic evaluation of salmeterol/fluticasone combination versus budesonide plus formoterol in Spain Source: Eur Respir J 2001; 18: Suppl. 33, 49s Year: 2001 Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001 Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010 LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003 A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD Source: Eur Respir J 2014; 43: 763-772 Year: 2014 Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient Source: Annual Congress 2010 - Management of airway disease Year: 2010 Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Source: Eur Respir J 2007; 29: 682-689 Year: 2007 Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children Source: Eur Respir J 2005; 26: Suppl. 49, 161s Year: 2005 Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005